Uso de anagrelide en la trombocitemia esencial y policitemia vera

• Autores: Vanessa Jorge Vidal, C. Funes Vera, S. Rabell Iñigo, Mª Carmen Mira Sirvent, Mónica Martínez Penella
• Localización: Atención Farmacéutica, ISSN 1139-7357, Vol. 7, Nº. 3, 2005, págs. 241-244
• Idioma: español
• Títulos paralelos:
  • Use of anagrelide in essential thrombocythemia and polycythemia vera
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objective: To describe the use of anagrelide in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Method: Retrospective analysis since January, 2002, to April, 2005 of the patients treated with anagrelide in our hospital. The levels of platelets at the beginning, after a month and after six months are obtained, as well as the previous and associated treatments, suspension and causes, thrombohemorrhagic phenomena and side effects. Results: Only 10 patients could be evaluated. The decrease in the number of platelets below 600 × 109/L was evaluated. At a month of treatment, 40% of patients responded, at six months, 70% and at a year, 70%. The side effects that they presented were light (headaches and tachycardia). Conclusion: Anagrelide is a good drug for controlling the thrombohemorrhagic manifestations in PV and ET, with light side effects